Review anchor
ATP-binding cassette sub-family C member 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
ATP-binding cassette sub-family C member 2
CHEMBL5748
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats ATP-binding cassette sub-family C member 2 as ChEMBL target CHEMBL5748, mapped to UniProt Q92887. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL5748
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q92887
ATP-binding cassette sub-family C member 2
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why ATP-binding cassette sub-family C member 2 matters
ATP-binding cassette sub-family C member 2 is reviewed as ATP-binding cassette sub-family C member 2 (UniProt Q92887); the current evidence base includes 27 approved drugs, 871 compounds, and 151 assays, with lead potency reaching pChEMBL 6.5.
Protein context
ATP-binding cassette sub-family C member 2
ATP-binding cassette sub-family C member 2 Sequence length is 1545 aa.
Review this target as ATP-binding cassette sub-family C member 2, mapped to UniProt Q92887. Sequence length is 1545 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q92887
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 27 approved drugs, 871 compounds, and 151 assays for this target. The dominant activity type is IC50. CHEMBL2074720 is the current potency anchor at pChEMBL 6.5.
Use CHEMBL2074720 as the tractability anchor when discussing potency (pChEMBL 6.5).
Activity source · ChEMBL 36 via Core Engine
27 approved
pChEMBL 6.5
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why ATP-binding cassette sub-family C member 2 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q92887, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
871
Total Compounds
151
Total Assays
27
Approved Drugs
IC50: 678.0, KI: 15.0, EC50: 6.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL2074720
|
6.5 | IC50 | — |
|
|
No preferred name
CHEMBL3038248
|
6.4 | IC50 | — |
|
|
No preferred name
CHEMBL1829174
|
5.6 | IC50 | Clinical |
|
|
No preferred name
CHEMBL160
|
5.5 | IC50 | Approved |
|
|
No preferred name
CHEMBL495936
|
5.5 | IC50 | — |
Source Header